Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

Dow Jones

Feb 10

2219 GMT - Imaging-tech provider Pro Medicus's share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what Pro Medicus offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. "Pro Medicus provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term," Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

February 09, 2026 17:19 ET (22:19 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610721661"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610721661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610721661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 06:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610721661","market":"sh","top_or_hot":-1,"title":"Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2219 GMT - Imaging-tech provider <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a>'s share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"<a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a> provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 09, 2026 17:19 ET (22:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-10 06:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2219 GMT - Imaging-tech provider <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a>'s share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"<a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a> provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 09, 2026 17:19 ET (22:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PME.AU","symbol_name":"PRO MEDICUS LTD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610721661","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610721661","pubTimestamp":1770675540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2219 GMT - Imaging-tech provider Pro Medicus's share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what Pro Medicus offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"Pro Medicus provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PME.AU":"PRO MEDICUS LTD","BK7094":"医疗保健技术"},"translate_title":"Pro Medicus的商业案例因人工智能的采用而更具吸引力——Market Talk","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PME.AU":0.9},"content_text":"2219 GMT - Imaging-tech provider Pro Medicus's share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what Pro Medicus offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"Pro Medicus provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 09, 2026 17:19 ET (22:19 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}